1 / 31

Heart Failure With Preserved And Impaired Systolic Left Ventricular Function In ALLHAT

ALLHAT. Heart Failure With Preserved And Impaired Systolic Left Ventricular Function In ALLHAT. JB Kostis, B Davis, L Simpson, H Black, W Cushman, P Einhorn, M Farber, C Ford, D Levy, B Massie, S Nawaz For The ALLHAT Collaborative Research Group. ALLHAT. Antihypertensive Trial Design.

brendan-powers
Download Presentation

Heart Failure With Preserved And Impaired Systolic Left Ventricular Function In ALLHAT

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. ALLHAT Heart Failure With Preserved And Impaired Systolic Left Ventricular Function In ALLHAT JB Kostis, B Davis, L Simpson, H Black, W Cushman, P Einhorn, M Farber, C Ford, D Levy, B Massie, S Nawaz For The ALLHAT Collaborative Research Group

  2. ALLHAT AntihypertensiveTrial Design • Randomized, double-blind, multi-center clinical trial • Determine whether occurrence of fatal CHD or nonfatal MI is lower for high-risk hypertensive patients treated with newer agents (CCB, ACEI, alpha-blocker) compared with a diuretic • 42,418 high-risk hypertensive patients ≥ 55 years

  3. ALLHAT Randomized Design of ALLHAT BP Trial 42,418 High-risk hypertensive patients Consent / Randomize Amlodipine Chlorthalidone Doxazosin Lisinopril Follow until death or end of study (4-8 years, mean 4.9 years)

  4. ALLHAT Rationale for the Heart Failure Validation Study: Background • Early termination of the doxazosin arm February 2000, due to: • 25% higher risk of CVD events in doxazosin compared to chlorthalidone, mostly driven by two-fold increase in HF • a very low probability of finding a significant difference for the primary outcome by the scheduled trial end • Higher risk of HF in amlodipine and lisinopril arms compared with chlorthalidone • ALLHAT DSMB recommended that this study be done

  5. ALLHAT Heart Failure Validation Study: Design and Methods • Protocol developed in collaboration with heart failure experts. • Additional documentation collected for all hospitalized heart failure events. • Documentation reviewed by cardiology fellows (blinded to treatment assignment), for signs, symptoms, past history, concomitant conditions, procedures, treatments. • Analyses performed using computer algorithm to determine whether each case met ALLHAT or Framingham criteria.

  6. HF With Preserved And Impaired Systolic Left Ventricular Function ALLHAT Introduction • Heart failure developing in patients with hypertension is associated either with preserved or with impaired left ventricular systolic function. • ALLHAT provides the to examine occurrence and differences in symptoms, signs and case fatality of heart failure with preserved or impaired left ventricular systolic function.

  7. ALLHAT HF With Preserved And Impaired Systolic Left Ventricular Function Methods • To verify the heart failure outcomes of ALLHAT, all available hospitalized heart failure events reported by ALLHAT Investigators were systematically reviewed. • Estimate of left ventricular ejection fraction by contrast ventriculography, echocardiography or radionuclide study was available in 928 (66%) of 1,300 first hospitalized heart failure events meeting ALLHAT criteria.

  8. ALLHAT 45% EF>50% EF<50% N=928 HF by EF level <50% vs. >50% HF With Preserved And Impaired Systolic Left Ventricular Function

  9. ALLHAT HF With Preserved And Impaired Systolic Left Ventricular Function EF>50% EF N/A EF 40-49% EF<40% N=1399 HF by EF level

  10. ALLHAT HF With Preserved And Impaired Systolic Left Ventricular Function EF<40% EF>50% EF 40-49% HF by EF level (% of those with available EF) N=928

  11. ALLHAT HF With Preserved And Impaired Systolic Left Ventricular Function

  12. ALLHAT HF With Preserved And Impaired Systolic Left Ventricular Function

  13. ALLHAT HF With Preserved And Impaired Systolic Left Ventricular Function

  14. HF With Preserved And Impaired Systolic Left Ventricular Function ALLHAT

  15. HF With Preserved And Impaired Systolic Left Ventricular Function ALLHAT

  16. HF With Preserved And Impaired Systolic Left Ventricular Function ALLHAT EF Range by Drug *lisinopril vs. chlorthalidone p=0.04

  17. HF With Preserved And Impaired Systolic Left Ventricular Function ALLHAT EF Range by Drug; % of Those With Available EF * lis vs. chlor, p=0.02

  18. HF With Preserved And Impaired Systolic Left Ventricular Function ALLHAT Total 37.1 P=0.004 28.1 P=0.02 P=0.06 Vital Status (% Dead)

  19. HF With Preserved And Impaired Systolic Left Ventricular Function ALLHAT Vital Status by Drug and EF Group

  20. ALLHAT 1.00 >50% 40 - 49% 0.80 <40% 0.60 Conditional Cumulative ALLHAT#1 HF Rate 0.40 0.20 0.00 0 1 2 3 4 5 6 7 Time to event, y Cumulative HF Rate Among All HF Cases Using ALLHAT Criteria; With EF by EF Class

  21. ALLHAT Cumulative HF Rate Among All HF Cases Using ALLHAT Criteria; With EF by EF Class 1.00 Normal (EF>50) Impaired (EF<50) 0.80 0.60 Conditional Cumulative ALLHAT#1 HF Rate 0.40 0.20 0.00 0 1 2 3 4 5 6 7 Time to event, y

  22. ALLHAT Chlorthalidone Amlodipine Lisinopril Cumulative HF Rate Using ALLHAT Criteria; With EF<50 0.03 0.02 Cumulative ALLHAT#1 HF Rate 0.01 0.00 0 1 2 3 4 5 6 7 Time to event, y

  23. ALLHAT Chlorthalidone Amlodipine Lisinopril Cumulative HF Rate Using ALLHAT Criteria; With EF>50 0.03 0.02 Cumulative ALLHAT#1 HF Rate 0.01 0.00 0 1 2 3 4 5 6 7 Time to event, y

  24. ALLHAT Chlorthalidone Doxazosin Cumulative HF Rate Using ALLHAT Criteria; With EF<50 0.02 0.01 Cumulative ALLHAT#1 HF Rate 0.00 0 1 2 3 4 Time to event, y

  25. ALLHAT Chlorthalidone Doxazosin Cumulative HF Rate Using ALLHAT Criteria; With EF>50 0.02 Cumulative ALLHAT#1 HF Rate 0.01 0.00 0 1 2 3 4 Time to event, y

  26. ALLHAT Chlorthalidone Amlodipine Lisinopril Post-HF Mortality With Preserved Systolic Function (EF >50) 0.80 0.70 0.60 0.50 0.40 Cumulative Post-HF Mortality Rate 0.30 0.20 0.10 0.00 0 1 2 3 4 5 6 Time to event, y

  27. ALLHAT Chlorthalidone Amlodipine Lisinopril Post-HF Mortality With Impaired Systolic Function (EF<50) 0.80 0.70 0.60 0.50 0.40 Cumulative Post-HF Mortality Rate 0.30 0.20 0.10 0.00 0 1 2 3 4 5 6 Time to event, y

  28. ALLHAT Doxazosin Chlorthalidone Post-HF Mortality With Preserved Systolic Function (EF >50) 0.80 0.70 0.60 0.50 Cumulative Post HF Mortality Rate 0.40 0.30 0.20 0.10 0.00 0 1 2 3 4 Time to event, y

  29. ALLHAT Doxazosin Chlorthalidone Post-HF Mortality With Impaired Systolic Function (EF<50) 0.80 0.70 0.60 0.50 Cumulative Post-HF Mortality Rate 0.40 0.30 0.20 0.10 0.00 0 1 2 3 4 Time to event, y

  30. ALLHAT Post-HF Mortality By Systolic Function 0.80 Preserved Systolic Function (EF >50) 0.70 Impaired Systolic Function (EF <50) 0.60 0.50 0.40 Cumulative ALLHAT#1 HF to Death Rate 0.30 0.20 0.10 0.00 0 1 2 3 4 5 6 Time to Event, y

  31. HF With Preserved And Impaired Systolic Left Ventricular Function ALLHAT Conclusions • Heart Failure with preserved left ventricular systolic function is common in treated patients with hypertension (compared to heart failure with impaired systolic function). • Heart Failure with preserved left ventricular systolic function is associated with more edema while heart failure with impaired left ventricular systolic function is associated with signs of ventricular dilatation. • Heart Failure with preserved left ventricular systolic function is associated with lower case fatality (than heart failure with impaired systolic function).

More Related